** Shares of drug developer Mersana Therapeutics MRSN.O fall 5.5% to 34 cents premarket
** MRSN announces restructuring and reprioritization plan to extend its cash and for further development of its experimental cancer drug, emiltatug ledadotin
** Restructuring plan will reduce workforce by about 55% across functions, expected to be substantially be complete by end of Q3 2025, MRSN says
** Co to also reduce its research activities and eliminate internal pipeline development efforts
** These actions are expected to provide co with sufficient cash resources to support its current operating plan commitments into mid-2026, MRSN says
** Brokerage William Blair says given stock pullback, this creates an attractive entry point into the story and offers an opportunity to gain access to the experimental therapy
** Up to last close, stock down 74.5% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。